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Abstract
An important tool to evaluate the performance of any design is an optimal
benchmark proposed by O’Quigley and others (2002, Biostatistics 3(1), 51-56) that
provides an upper bound on the performance of a design under a given scenario.
The original benchmark can be applied to dose finding studies with a binary end-
point only. However, there is a growing interest in dose finding studies involving
continuous outcomes, but no benchmark for such studies has been developed. We
show that the original benchmark and its extension by Cheung (2014, Biometrics
70(2), 389-397), when looked at from a different perspective, can be generalized
to various settings with several discrete and continuous outcomes. We illustrate
and compare the benchmark performance in the setting of a Phase I clinical trial
with continuous toxicity endpoint and in the setting of a Phase I/II clinical trial
with continuous efficacy outcome. We show that the proposed benchmark provides
an accurate upper bound for model-based dose finding methods and serves as a
powerful tool for evaluating designs.
Keywords: Continuous endpoint; Dose finding; Non-parametric optimal design;
Phase I; Phase I/II
1 Introduction
A variety of dose finding methods for Phase I clinical trials aiming to find the maximum
tolerated dose (MTD) were proposed in the literature in past three decades. The con-
ventional way to assess the performance of a design is to conduct an extensive simulation
study. One of the key characteristics of any dose-finding method is its accuracy which
is usually computed as the proportion of times the correct dose is selected. The major-
ity of novel proposals are studied in scenarios chosen by investigators themselves. This,
clearly, adds subjectivity to the assessment of the method’s operating characteristics as
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one can always find scenarios in which the MTD identification is easier than in others.
To solve this problem, O’Quigley and others (2002) proposed the non-parametric optimal
benchmark that provides an upper limit of accuracy (in terms of proportion of correct
selections) for dose finding methods based on a binary toxicity endpoint. The benchmark
uses the concept of the complete information which assumes that outcomes of each patient
can be observed at all dose levels (in contrast to an actual trial in which patients can be
assigned to one dose only). The benchmark shows how ‘difficult‘ the MTD identification
is in the chosen scenario and provides the objective context for the performance evalu-
ation of the design under investigation. Since its proposal, the benchmark has proven
its great usefulness by the ability to assess the newly proposed designs comprehensively
(see e.g. Paoletti and Kramar, 2009; Yin and Yuan, 2009). Additionally, based on the
benchmark, Cheung (2013) derived sample size formulae for the continual reassessment
method (CRM) by O’Quigley and others (1990).
The benchmark was originally proposed for studies with a binary endpoint. Mo-
tivated by more complex studies, for instance, Phase I/II clinical trials evaluating bi-
nary toxicity and efficacy endpoints simultaneously (Thall and Russell, 1998) or Phase
I trials with multiple grades of toxicities (Lee and others , 2011), Cheung (2014) gener-
alized the benchmark to both of these cases. This has broadened the application of the
benchmark significantly. However, there is a growing number of Phase I and Phase I/II
clinical trials involving continuous endpoints, but no corresponding benchmark exists yet.
For example, Bekele and Thall (2004); Yuan and others (2007); Ivanova and Kim (2009);
Bekele and others (2010); Ezzalfani and others (2013); Wang and Ivanova (2015), consid-
ered a continuous toxicity endpoint while, for example, Bekele and Shen (2005); Hirakawa
(2012); Yeung and others (2015, 2017) studied Phase I/II trials with binary toxicity and
continuous efficacy endpoints.
In this work, we propose a simple benchmark which can be applied to dose finding
studies with continuous outcomes. The novel benchmark employs the same concept of the
complete information as the original method and is based on the well-known probability
integral transform. This general method also allows to find a benchmark for designs with
multiple correlated outcomes and several treatment cycles. It is shown that the evaluation
of the novel benchmark does not require any additional information other than already
provided in the simulation study of a design. We apply the novel benchmark to evaluate
the performance of two recently proposed dose finding methods: a design for a Phase I
trial with continuous toxicity endpoint and a design for a Phase I/II trial with binary
toxicity and continuous efficacy endpoints.
In Section 2, we review the original benchmark and propose its generalization. We
compare design proposals for Phase I and Phase I/II to the benchmark in Section 3 and
conclude with a discussion.
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2 Methods
2.1 Benchmark for Binary Endpoint
Consider a Phase I clinical trial with a binary toxicity outcome, dose-limiting toxicity
(DLT) or no DLT, n patients and a discrete set of dose levels d1, . . . , dm. Let Yij be a
Bernoulli random variable taking value yij = 0 if patient i has experienced no DLT at
dose dj and yij = 1 otherwise. This random variable is characterised by probability pj
such that pj = P (Yij = 1), i = 1, . . . , n. The goal of the trial is to find the maximum
tolerated dose (MTD), the dose corresponding to a prespecified risk of toxicity, γ.
The non-parametric optimal benchmark uses the concept of the complete information.
For a given patient the complete information consists of the vector of outcomes (DLT
or no DLT) at all dose levels assuming that p1, . . . , pm are known. In other words, for a
given patient one knows the maximum toxicity probability that this patient can tolerate.
Formally, the information about the DLT of patient i at each dose level is summarised
in a single value ui ∈ (0, 1), which is drawn from a uniform distribution, U(0, 1). For
instance, ui = 0.3 means that patient i can tolerate doses dj with pj ≤ 0.3, but would
observe a DLT if given dose dj′ with pj′ > 0.3. It follows that ui is transformed to yij = 0
for doses with pj < 0.3 and to yij = 1 otherwise. The procedure is repeated for all n
patients which results in the vector of responses for each dose level yj = (y1j, . . . , ynj),
j = 1, . . . , m. Let T (yj , γ) be a summary statistic for the dose level dj upon which the
decision about the MTD selection is based. Conventionally, T (yj , γ) is chosen such that
its minimum (or maximum) value corresponds to the estimated MTD. Therefore, dj for
which T (yj) is minimised (maximised) for all j = 1, . . . , m is declared as the MTD in
a single trial. The procedure is repeated for S simulated trials and then proportions of
each dose selected as the MTD is computed.
In a context of a Phase I clinical trial with binary response
T (yj , γ) =
∣∣∣
∑n
i=1 yij
n
− γ
∣∣∣ (2.1)
is a conventional choice for the MTD selection criterion. We refer the reader to the Web
application by Wages and Varhegyi (2017) for the benchmark evaluation using criterion
(2.1).
2.2 Benchmark for Continuous Endpoint
Consider now a Phase I clinical trial with continuous outcome Yij at dose dj for patient
i having cumulative distribution function (CDF) Fj(y). The goal of the trial is find the
target dose (TD) which minimises (or maximises as defined by an investigator) some deci-
sion criterion T (·). In simulations the CDF, Fj, is chosen by an investigator and specifies
the distribution of outcomes for a given dose dj, and the set of CDFs corresponding to
doses d1, . . . , dm defines a simulation scenario. This simple fact is going to be a central
part of our proposal. To illustrate the construction of the novel benchmark step-by-step,
we use a setting studied by Wang and Ivanova (2015) throughout this section.
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Example 1. Wang and Ivanova (2015) considered a setting with m = 6 doses and a
biomarker for toxicity measured on a continuous scale. In one of the simulation scenar-
ios presented, it is assumed that a toxicity outcome Yij given dose level dj has normal
distribution N (0.1j, (0.1j)2), j = 1, . . . , 6. Then, the CDF Fj is the CDF of a normal
random variable with corresponding parameters Φ(·, µj = 0.1j , σ2 = (0.1j)2). These
CDFs will be used to obtain the benchmark in this scenario.
Let us denote the quantile transformation as
F−1j (x) = inf{y|Fj(y) ≥ x}, 0 < x < 1. (2.2)
Then,
Probability integral transform. If U ∼ U(0, 1) is a uniform random variable on the
unit interval, then Fj is the cumulative distribution function of a random variable F
−1
j (U).
This result is commonly used for inverse transform sampling (e.g. see Bekele and Shen,
2005, for an example in dose finding) which allows to generate a random variable with
any distribution Fj .
Assume that the whole information about a patient’s profile is summarised in a single
value ui drawn from U(0, 1). For patient i with profile ui, the quantile transformation
yij = F
−1
j (ui) is applied to obtain a continuous outcome that this patient would have at
dose dj, j = 1, . . . , m. Different dose levels are modelled by applying the quantile trans-
formation using corresponding CDFs. This results in a vector of responses (yi1, . . . , yim),
also called the complete information about patient i. The same procedure is repeated
for all patients i = 1, . . . , n which, again, results in the vector of responses for each dose
level yj = (y1j , . . . , ynj), j = 1, . . . , m.
Example 1 (Continued). Following the setting by Wang and Ivanova (2015), assume
that the first patient has a toxicity profile u1 = 0.40. The benchmark answers the ques-
tion ”how would patient 1 respond to dose level dj with response having distribution
N (0.1j, (0.1j)2)”. Applying the corresponding quantile transformation, the response of
patient 1 given the dose level d1 is equal to y11 = Φ
−1(u1 = 0.40, µj = 0.1, σ
2 = 0.12) ≈
0.075. Subsequently, the complete information about patient 1 consists in the vector of
responses at all dose levels d1, . . . , d6
(0.075, 0.149, 0.224, 0.299, 0.373, 0.448).
The complete information for 5 patients with randomly generated profiles u1, . . . , u5 is
given in Table 1.
Recalling the decision criterion T (yj) on which the TD selection is based, the dose
level dj for which T (yj) is minimised (or maximised) is declared as the TD in a single
trial. For instance, if the goal of the trial is to find the dose having the average level of
toxicity γ, the decision criterion (2.1) can be used. The benchmark can be constructed for
various decision criteria and then be adapted to evaluate any design under investigation.
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Table 1: The complete information for 5 patients with randomly generated toxicity pro-
files.
Patient’s profile ui
Patient’s response
d1 d2 d3 d4 d5 d6
u1 = 0.40 0.075 0.149 0.224 0.299 0.373 0.448
u2 = 0.25 0.033 0.065 0.098 0.130 0.163 0.195
u3 = 0.92 0.241 0.481 0.722 0.962 1.203 1.443
u4 = 0.67 0.144 0.288 0.432 0.576 0.720 0.864
u5 = 0.31 0.050 0.101 0.151 0.202 0.252 0.302
Mean 0.109 0.217 0.325 0.434 0.542 0.650
Variance 0.007 0.029 0.065 0.116 0.181 0.261
Example 1 (Continued). The goal of the trial considered by Wang and Ivanova (2015)
is to find the dose with the mean response closest to the target response γ. The criterion
of choosing the dose which maximises the probability of the average level of toxicity µj
to be in the ε neighbourhood of γ was considered. Let gj(·|yj) be a probability density
function of µj given the data yj. Then, the decision criterion takes the form
T (yj) =
∫ γ+ε
γ−ε
gj(v|yj)dv. (2.3)
The TD is the dose for which the criterion T (yj) is maximised. Following the original
framework, γ = 0.1 and ε = 0.01 are chosen. Using the complete information gener-
ated in Table 1 and the density function of Normal distribution with corresponding mean
and variance parameters yields: T (y1) = 0.09; T (y2) = 0.04; T (y3) = 0.02; T (y4) =
0.01; T (y5) = 0.01 and T (y6) = 0.01. The value of the criterion is maximised for dose
level d1 which is selected as the TD in this single trial. The procedure is repeated for
s = 1, . . . , S simulated trial to obtain the proportion of correct selections. The evaluation
of the method by Wang and Ivanova (2015) using the proposed benchmark is provided in
Section 3.1.
Algorithm 1 provides the step-by-step guidance how the benchmark can be con-
structed based on S simulated trials.
Algorithm 1 Computing a benchmark for a single continuous outcome
1. Specify CDFs Fj for all doses dj, j = 1, . . . , m and define the decision criterion T (·)
2. Generate a sequence of patients’ profiles {ui}ni=1 from uniform distribution U(0, 1).
3. Transform ui for dose level dj using yij = F
−1
j (ui), i = 1, . . . , n, j = 1, . . . , m and
store yj = (y1j, . . . , ynj).
4. Compute T (yj) for all j = 1, . . . , m, find dose J for which T (yJ) is maximised
(minimised) and set Zs = J .
5. Repeat steps 2-4 for s = 1, . . . , S simulated trials
6. Use Z¯(j) =
∑S
s=1 I (Zs = j) /S as the selection proportion of dose dj, j = 1, . . . , m
The proposed benchmark can be applied to a wide range of distributions as it requires
the quantile information only, which is available for many distributions in various statis-
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tical software (for example, qbinom, qnorm, qexp , etc in R (R Core Team, 2015)). Note
that the probability integral transform can be also applied to discrete random variables
in which case the quantile transformation F−1j (·) is given explicitly. It is easy to see that
using the F−1j (·) corresponding to a Bernoulli random variable in Algorithm 1 results in
the original benchmark construction proposed by O’Quigley and others (2002).
The novel the benchmark can be also applied to clinical trials with multiple endpoints.
This construction is provided below.
2.3 Benchmark for Multiple Endpoints
In the setting with several endpoint, the correlation between them is important. Be-
low, we describe the algorithm generating correlated outcomes in the benchmark frame-
work. In fact, the approach described below has been known for a long time (Tate, 1955;
Molenberghs and others , 2001). We apply it to an arbitrary distribution of outcomes
to generate the complete information. We start from the case of binary toxicity and
continuous efficacy that has attracted a lot of attention in the literature recently.
Consider a Phase I/II clinical trial with toxicity outcome Y
(1)
ij and efficacy outcome
Y
(2)
ij with CDFs F
(1)
j and F
(2)
j , respectively, at dose level dj for patient i. We will use the
setting studied by Bekele and Shen (2005) to illustrate the construction of the benchmark
for multiple endpoint through this section.
Example 2. Bekele and Shen (2005) considered a setting with m = 4 dose levels, an
efficacy outcome at dose dj with Gamma distribution Γ(λjτ, τ) where λjτ is the shape
parameter, τ = 0.1 is the rate parameter (i.e., the mean equals to λj), and a DLT outcome
having probability pj. In one of the simulation scenarios the following parameters are
assumed λ1 = 25, λ2 = 60, λ3 = 115, λ4 = 127 and p1 = 0.01, p2 = 0.10, p3 =
0.25, p4 = 0.60. Then, F
(1)
j is the CDF of a Bernoulli random variable with parameter pj
and G(·, λjτ, τ) is the CDF of a Gmma random variable with parameter λj, j = 1, 2, 3, 4.
The toxicity/efficacy profile of patient i is given by two characteristics: u
(1)
i ∈ (0, 1)
corresponding to toxicity and u
(2)
i ∈ (0, 1) corresponding to efficacy. Firstly, we generate
a bivariate standard normal vector (x
(1)
i , x
(2)
i ) with mean µ = (0, 0) and covariance matrix
Σ =
[
1 ρ
ρ 1
]
(2.4)
where ρ is the correlation coefficient. In a simulation study, the correlation coefficient, ρ,
is specified by the investigator as part of the simulation scenario. By applying the CDF
of the standard normal random variable (u
(1)
i , u
(2)
i ) = (Φ(x
(1)
i ),Φ(x
(2)
i )), one can obtain
two correlated random variables with uniform distributions. Then, the corresponding
quantile transformations are applied to u
(1)
i and u
(2)
i marginally as described in Section
2.2 and values of response for patient i at dose levels dj are obtained y
(1)
ij = F
−1(1)
j (u
(1)
i ),
y
(2)
ij = F
−1(2)
j (u
(2)
i ). This results in the complete vector of toxicity and efficacy outcomes
at all dose level for the patient i. The procedure is repeated for n patients and pairs of
vectors y
(1)
j = (y
(1)
1j , . . . , y
(1)
nj ) and y
(2)
j = (y
(2)
1j , . . . , y
(2)
nj ) are obtained for each dose level
dj, j = 1, . . . , m.
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Example 2 (Continued). The correlation coefficient considered by Bekele and Shen (2005)
is ρ = 0.25. The bivariate normal vector with mean µ = (0, 0) and covariance matrix
Σ is initially generated: (x1, x2) = (−0.892, 0.292). Then, the first patient has a toxi-
city profile u
(1)
1 = Φ(−0.892) = 0.186 and an efficacy profile u
(2)
1 = Φ(0.292) = 0.615
which corresponds to toxicity response F−1
(1)
1 (u
(1)
1 = 0.186, p1 = 0.01) = 0 (applying
the quantile transformation of Bernoulli distribution) and efficacy response G−1(u
(2)
1 =
0.615, λ1 τ = 2.5, τ = 0.1) = 26.3 (apply the quantile transformation of Gamma dis-
tribution). Subsequently, the vector of the complete toxicity information is (0, 0, 1, 1) and
the vector of the complete efficacy information is (26.3, 74.6, 121.8, 134.3). The complete
information for 5 patients with random generated profiles u
(1)
1 , u
(2)
1 , . . . , u
(1)
5 , u
(2)
5 is given
in Table 2.
Table 2: The complete information for 5 patients with randomly generated toxicity and
efficacy profiles.
Patient’s profile ui
Patient’s response
d1 d2 d3 d4 d5 d6
u
(1)
1 = 0.186 0 0 1 1
u
(2)
1 = 0.615 26.3 74.6 121.8 134.3
u
(1)
2 = 0.390 0 0 0 1
u
(2)
2 = 0.214 12.2 48.4 87.3 97.3
u
(1)
3 = 0.618 0 0 0 0
u
(2)
3 = 0.898 45.7 104.7 159.3 173.5
u
(1)
4 = 0.456 0 0 0 1
u
(2)
4 = 0.545 23.6 70.0 112.9 128.1
u
(1)
5 = 0.683 0 0 0 0
u
(2)
5 = 0.869 42.5 99.9 153.5 167.4
Number of toxicities 0 0 1 3
Mean (efficacy) 30.1 79.5 127.5 140.2
Standard Deviation (efficacy) 13.8 23.0 29.5 30.8
Similar to a single endpoint case, the TD selection is based on a pre-specified decision
criterion, T (y
(1)
j ,y
(2)
j ), which takes the minimum (maximum) value for the most desirable
dose level. This would, however, involve the information for all endpoints of interest and
can have more complicated structure. In the context of the Phase I/II clinical trial the
decision criterion is also known as a trade-off function (see e.g. Thall and Cook, 2004).
Example 2 (Continued). Bekele and Shen (2005) defined the target dose as the dose
with the highest expected efficacy while being safe (pj < 0.35) and efficacious (λj > 5).
This translates in the criterion
T (y
(1)
j ,y
(2)
j ) =
∑n
i=1 y
(2)
ij
n
× I
(∫ 5
0
g
(2)
j (v|y
(2)
j )dv < θ
(1)
)
× I
(∫ 0.35
0
g
(1)
j (v|y
(1)
j )dv > θ
(2)
)
(2.5)
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where g
(1)
j (·|y
(1)
j ) and g
(2)
j (·|y
(2)
j ) are probability density functions of an efficacy response
and of a toxicity probability given the data y
(1)
j ,y
(2)
j , respectively, and θ
(1), θ(2) are con-
trolling probabilities. This decision criterion is used to construct the benchmark in this
setting. Applied to the benchmark, the integrals in (2.5) are computed using density
functions of Beta distribution and Normal distribution for toxicity and efficacy out-
comes, respectively. Using summary statistics given in Table 2 and controlling proba-
bilities θ(1) = θ(2) = 0.50, values of the criterion are T (y
(1)
1 ,y
(2)
1 ) = 0.30; T (y
(1)
2 ,y
(2)
2 ) =
0.79; T (y
(1)
3 ,y
(2)
3 ) = 1.28; T (y
(1)
4 ,y
(2)
4 ) = 0;. The criterion is maximised for dose level d3
which is selected as the TD in this single trial. The procedure is repeated for s = 1, . . . , S
simulated trials to obtain the proportion of correct selections. The evaluation of the
method by Bekele and Shen (2005) using the proposed benchmark is provided in Section
3.2.
Similarly, the benchmark can be applied to an arbitrary number of endpoints. For
instance, consider a Phase I/II trial in which toxicity and efficacy are evaluated in four
cycles. Then, the profile of patient i is given by u
(1)
i , . . . , u
(8)
i each drawn from U(0, 1)
and the rest of the construction remains unchanged. The procedure to generate the
benchmark for K endpoints is given in Algorithm 2.
Algorithm 2 Computing a benchmark for multiple outcomes
1. Specify K ×K covariance matrix Σ and define objective function T (·).
2. Generate xi = (x
(1)
i , . . . , x
(K)
i ), i = 1, . . . , n from N (µ,Σ) where µ = [0, . . . , 0]1×K
3. Compute ui = (u
(1)
i , . . . , u
(K)
i ), i = 1, . . . , n applying CDF Φ to each component of
xi.
4. Apply the quantile transformation y
(k)
ij = F
−1
j
(k)
(u
(k)
i ) for k = 1, . . . , K at each
dose level dj, j = 1, . . . , m and for i = 1, . . . , n as described in Algorithm 1 and store
y
(k)
j = (y
(k)
1j , . . . , y
(k)
nj )
5. Compute T (y
(1)
j , . . . ,y
(K)
j ), j = 1, . . . , m, find dose level J for which T (·) is max-
imised (minimised) and set Zs = J .
6. Repeat steps 2-5 for s = 1, . . . , S simulated trials
7. Use Z¯(j) =
∑S
s=1 I (Zs = j) /S as the selection proportion of dose dj, j = 1, . . . , m
In the following section, we illustrate the implementation of Algorithm 1 (in Section
3.1) and Algorithm 2 (in Section 3.2) in different clinical contexts.
3 Application
3.1 Continuous Toxicity in Phase I Trials
The dichotomization of the toxicity endpoint (DLT/no DLT) in Phase I clinical trials
restricts the available information about the drug’s toxicity. In fact, a continuous toxic-
ity endpoint can provide a better insight on the drug’s profile (Wang and others , 2000;
Bekele and Thall, 2004; Wang and Ivanova, 2015).
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Recently, Wang and Ivanova (2015) proposed the Bayesian Design for Continuous
Outcomes (BDCO) which can be applied to clinical trials with continuous toxicity end-
point. In short, BDCO assumes that outcome Yij at dose dj for patient i has normal
distribution N (µj, σ2j ) where µj is considered as a random variable itself. Based on the
posterior distributions of µj, BCDO is driven by the probability that µj is within ε of
the target, γ:
pij = P (γ − ε ≤ µj ≤ γ + ε) . (3.1)
The design targets the dose which maximizes the probability in (3.1). This is equivalently
to maximising the decision criterion T (·) given in Equation (2.3). Below, we apply the
proposed benchmark to the setting considered in the original paper using this decision
criterion and compare its performances to BDCO.
Recalling the setting by Wang and Ivanova (2015), we consider six scenarios with six
dose levels d1, . . . , d6, a sample size of n = 36, parameter ε = 0.01 and two cases: (i) the
case of equal variances in which outcome Yij has normal distribution N (0.1j, 0.22) and (ii)
the case of unequal variances corresponding to normal distributions N (0.1j, 0.12j2). In
each of six scenarios the target values γ = {0.1, 0.2, 0.3, 0.4, 0.5, 0.6} are used, respectively.
As a consequence, the target dose is dose d1 in scenario 1, d2 in scenario 2, and so on.
Table 3 shows the operating characteristics of the BDCO against the benchmark. The
results of the BDCO are extracted from Table 2 in the original article, and the benchmark
is evaluated using S = 106 trial replications.
Under Scenarios 2-5, the proportion of correct selection using the benchmark is 87%,
which illustrates that they have the same level of ”complexity”. Conversely, the bench-
mark shows that it is easier to find the MTD if it is either the first or the last dose. Under
all scenarios with equal variances, the BCDO has the accuracy close to the benchmark.
The ratio of the probability of correct selection of the BCDO relative to the benchmark
ranges between 92% and 98% in these cases.
Under Scenarios with unequal variances, the benchmark demonstrates that it is harder
to find the MTD if the corresponding variance is high. For example, the benchmark
leads to 86% of correct selections under Scenario 2 and 45% under Scenario 5. Again,
it appears that it is easier to find the MTD when it is the first or the last dose for any
methods. BCDO shows very high accuracy in Scenario 1-5 with unequal variance. The
correct probability ratios never go below 91% and even reach nearly 100% under Scenario
5. In the former case, BCDO recommends the MTD in 45% of replications (as well as
the benchmark), but it recommends the highest dose d6 systematically less often - 20%
against 29% by the benchmark. This implies that BCDO tends to more conservative
decisions. Scenario 6 confirms this finding in which the correct probability ratio equals
76% which, however, is still high.
Overall, BCDO selects the correct dose uniformly less often than the benchmark in all
scenarios (as expected), but the efficiency of the design is high. The minimum ratio of the
probability of correctly selecting is 76% which corresponds to highly variable outcomes.
This indicates that parameters of the BCDO are adequately calibrated and the BCDO
in the proposed form is able to find the MTD in various scenarios.
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Table 3: Comparison of the BCDO against the respective benchmark.
Design Variance Percent of selecting dose
d1 d2 d3 d4 d5 d6
Scenario 1 in Wang and Ivanova (2015)
BCDO
Equal
0.91 0.10 0.00 0.00 0.00 0.00
Benchmark 0.94 0.06 0.00 0.00 0.00 0.00
BCDO
Unequal
0.97 0.03 0.00 0.00 0.00 0.00
Benchmark 0.98 0.02 0.00 0.00 0.00 0.00
Scenario 2 in Wang and Ivanova (2015)
BCDO
Equal
0.07 0.86 0.08 0.00 0.00 0.00
Benchmark 0.07 0.87 0.07 0.00 0.00 0.00
BCDO
Unequal
0.04 0.84 0.11 0.01 0.00 0.00
Benchmark 0.02 0.86 0.11 0.00 0.00 0.00
Scenario 3 in Wang and Ivanova (2015)
BCDO
Equal
0.00 0.07 0.83 0.09 0.00 0.00
Benchmark 0.00 0.07 0.87 0.07 0.00 0.00
BCDO
Unequal
0.00 0.16 0.65 0.16 0.02 0.00
Benchmark 0.00 0.11 0.69 0.17 0.02 0.00
Scenario 4 in Wang and Ivanova (2015)
BCDO
Equal
0.00 0.00 0.08 0.81 0.11 0.00
Benchmark 0.00 0.00 0.07 0.87 0.07 0.00
BCDO
Unequal
0.00 0.00 0.27 0.50 0.18 0.04
Benchmark 0.00 0.00 0.19 0.55 0.20 0.05
Scenario 5 in Wang and Ivanova (2015)
BCDO
Equal
0.00 0.00 0.00 0.09 0.80 0.11
Benchmark 0.00 0.00 0.00 0.07 0.87 0.07
BCDO
Unequal
0.00 0.00 0.02 0.34 0.45 0.20
Benchmark 0.00 0.00 0.00 0.25 0.45 0.29
Scenario 6 in Wang and Ivanova (2015)
BCDO
Equal
0.00 0.00 0.00 0.00 0.10 0.90
Benchmark 0.00 0.00 0.00 0.00 0.07 0.93
BCDO
Unequal
0.00 0.00 0.00 0.07 0.40 0.54
Benchmark 0.00 0.00 0.00 0.02 0.27 0.71
3.2 Continuous Efficacy and Binary Toxicity in Phase I/II Tri-
als
Similarly to the continuous toxicity outcome, the continuous efficacy endpoint can provide
better guidance on the target dose selection than the dichotomized one. One of the first
designs proposed for Phase I/II clinical trial considering continuous efficacy outcome is
by Bekele and Shen (2005) who developed a Bayesian approach to model toxicity and
(continuous) biomarker of efficacy jointly. We denoted this design by BS.
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Bekele and Shen (2005) introduced a latent normal random variable which is related to
the observed binary toxicity. A bivariate normal distribution allows for different strengths
of the dependence between toxicity and efficacy. Dose escalation/de-escalation decision
rules are based on the posterior distribution of both toxicity and efficacy. The design was
shown to have good operating characteristics in many scenarios. Therefore, the majority
of subsequently proposed designs (e.g. see Hirakawa (2012) and Yeung and others (2015))
were compared to it. Below, we provide the comparison of the design by Bekele and Shen
(2005) against the respective benchmark.
Recalling the framework by Bekele and Shen (2005) we consider an efficacy outcome
at dose dj having a Gamma distribution Γ(λjτ, τ) with rate parameter τ = 0.1 and
a DLT outcome having probability pj . A total of six scenarios and four dose levels
per scenario are explored using the total sample size n = 36. The parameters of λj
and toxicity probability pj are given in Table 4. In each scenario a weak association,
ρ = 0.25, between the toxicity and efficacy biomarker is used. The target dose is defined
as given in the criterion (2.5) - the dose with the highest expected efficacy while being
safe (pj < 0.35) and efficacious (λj > 5).
Table 4 shows the operating characteristics of the BS design against the respective
benchmark. The results for BS are extracted from Table 1 of the original work which
uses 1000 replications, and the benchmark is evaluated using S = 106 trial replications.
Under Scenarios 1, 3 and 5 with an increasing dose-efficacy relationship, the BS design
performs with high accuracy and the proportion of correct selections is close to the
benchmark. Interestingly, the BS design recommends the target dose d3 3% more often
than the benchmark under Scenario 1. Given the number of replications for the BS and
the benchmark, 3% difference is significant. This can be an indication that the prior
distribution used by BS is in favour of d3. It would also explain the relatively lower
performance under Scenario 4 in which the BS recommends the target dose d2 in 83%
of trials against 100% by the benchmark. The BS recommends the dose with the same
efficacy, but noticeably greater toxicity in 17% of trials. An alternative explanation of the
difference in proportion of selections under Scenario 4 can be a plateau in dose-efficacy
relation that is not modelled by the BS. Nevertheless, the ratio of correct probabilities is
83% demonstrating good operating characteristics of the BS design.
Under unsafe Scenario 2 and inefficacious Scenario 6, the BS design comes to the
correct conclusion nearly the same proportion of trials as the benchmark. This shows the
ability of the BS design to avoid the unethical selections due to either high toxicity or
low activity.
Overall, the benchmark confirmed that the BS design is flexible and can recommend
the target dose under many different scenarios. It also gives some possible clue to the
super-efficient performance under Scenario 1 and to a potential challenges that the BS
design can face in the plateau dose-efficacy scenarios.
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Table 4: Comparison of the BS against the respective benchmark.
Design Percent of selecting dose
d1 d2 d3 d4 None
Scenario 1 in Bekele and Shen (2005)
(λj, pj) (25,0.01) (70,0.10) (115,0.25) (127,0.60)
BS 0.00 0.03 0.95 0.02
Benchmark 0.00 0.08 0.92 0.00 0.00
Scenario 2 in Bekele and Shen (2005)
(λj, pj) (5,0.50) (70,0.70) (90,0.80) (135,0.85)
BS 0.06 0.00 0.00 0.00 0.94
Benchmark 0.02 0.00 0.00 0.00 0.98
Scenario 3 in Bekele and Shen (2005)
(λj, pj) (25,0.03) (46,0.05) (90,0.10) (135,0.15)
BS 0.00 0.00 0.02 0.98 0.00
Benchmark 0.00 0.00 0.01 0.99 0.00
Scenario 4 in Bekele and Shen (2005)
(λj, pj) (20,0.05) (75,0.05) (75,0.35) (75,0.65)
BS 0.00 0.83 0.17 0.00 0.00
Benchmark 0.00 1.00 0.00 0.00 0.00
Scenario 5 in Bekele and Shen (2005)
(λj, pj) (60,0.05) (65,0.50) (80,0.70) (95,0.85)
BS 0.94 0.06 0.00 0.00 0.00
Benchmark 0.97 0.03 0.00 0.00 0.00
Scenario 6 in Bekele and Shen (2005)
(λj, pj) (2,0.03) (2,0.03) (2,0.03) (2,0.03)
BS 0.01 0.00 0.00 0.00 0.99
Benchmark 0.01 0.00 0.00 0.00 0.99
4 Discussion
In this work, the novel benchmark for dose finding studies is formulated. In essence,
the novel benchmark is similar to the original proposal by O’Quigley and others (2002)
as the whole information about a patient is summarised in a single value u, but can be
also applied to studies with continuous outcomes. In the era of increasing complexity
of clinical trial the procedure evaluating an adequacy of the novel dose finding methods
is crucial. As it is shown above, the proposed benchmark provide an accurate upper
limit on the performance of model-based dose finding design. It is also able to reveal
some inadequacy in the model/parameter/prior specifications or, alternatively, confirm
the robustness of the design. The benchmark assesses the complexity of scenarios and
can serve as a standardization of scenarios of various difficulty. Therefore, it should be
definitely recommended for the complete analysis of the dose finding design as it helps
to evaluate the dose finding designs in more comprehensive way.
The possibility of the benchmark application to several endpoints allows to investigate
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the influence of the correlated outcomes on design’s characteristics which is an important
aspect of a Phase I/II dose finding studies. Moreover, it worth investigation what cor-
relation structure on the endpoints of interest the used method of correlated outcomes
generating implies. Clearly, the outcomes of the interest may no longer have the same
correlation ρ.
Finally, it is important to mention that while the benchmark is a useful tool for
assessing performances of any given dose finding methods, it does not capture all aspects
of the evaluation. For instance, it does not provide information on the distribution of dose
allocation, average number of DLTs or stopping rules. Developments in this direction are
of the great value for the complete design assessment.
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